MASS News and Press, 908 Devices Inc. From 10/19/22

908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

REBEL mass spec device used to reduce toxic metabolite accumulation while increasing cell viability and titer by up to 40% 908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, announced that its colla...

Image source: The Motley Fool. 908 Devices Inc. (NASDAQ: MASS) Q2 2022 Earnings Call Aug 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: 908 Devices Inc. (MASS) Q2 2022 Earnings Call Transcript

908 Devices Inc. (MASS) Q2 2022 Earnings Conference Call August 09, 2022 08:30 AM ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Chief Executive Officer & Co-Founder Joe Griffith - Chief Financial Officer Conference Call Participa...

908 Devices press release ( NASDAQ: MASS ): Q2 GAAP EPS of -$0.26 in-line. Revenue of $11.1M (+34.2% Y/Y) beats by $0.31M . For further details see: 908 Devices GAAP EPS of -$0.26 in-line, revenue of $11.1M beats by $0.31M

Q2 2022 revenue increases 34% over prior year, with gross margin of 60% 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended June 30, ...

908 Devices ( NASDAQ: MASS ) completed the acquisition of privately-held Braunschweig, Germany-based TRACE Analytics, provider of on-line analysis and sampling systems for biotech applications. The purchase consideration includes an initial cash payment of $15.3M...

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announces that it has completed the acquisition of privately-held TRACE Analytics GmbH , based in Braunschweig, Germany, a provider of on-l...

908 Devices ( NASDAQ: MASS ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.26 (+3.7% Y/Y) and the consensus Revenue Estimate is $10.79M (+30.5% Y/Y). Over the last 3 months, EPS estimates have...